Aerie Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Aerie Pharmaceuticals's estimated annual revenue is currently $24.2M per year.
- Aerie Pharmaceuticals received $86.2M in venture funding in January 2018.
- Aerie Pharmaceuticals's estimated revenue per employee is $137,392
- Aerie Pharmaceuticals's total funding is $993.1M.
Employee Data
- Aerie Pharmaceuticals has 176 Employees.
- Aerie Pharmaceuticals grew their employee count by -54% last year.
Aerie Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Global VP, Regulatory Affairs and Quality | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP, Portfolio Development | Reveal Email/Phone |
4 | VP Market Access | Reveal Email/Phone |
5 | VP, Business Development | Reveal Email/Phone |
6 | VP Implant Manufacturing Science and Technology | Reveal Email/Phone |
7 | VP Finance | Reveal Email/Phone |
8 | VP, Medical Affairs | Reveal Email/Phone |
9 | VP, Research and Discovery | Reveal Email/Phone |
10 | Director, Transparency and Sales Operations | Reveal Email/Phone |
Aerie Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.8M | 29 | 4% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $83.2M | 414 | 7% | N/A | N/A |
#4 | $31M | 154 | 56% | N/A | N/A |
#5 | $66.6M | 265 | 0% | $35M | N/A |
#6 | $10.9M | 54 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -6% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $26.5M | 132 | -11% | $637.8K | N/A |
#10 | $49.4M | 246 | 6% | N/A | N/A |
What Is Aerie Pharmaceuticals?
Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care. Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialisation of first-in-class therapies for the treatment of glaucoma and other diseases of the eye. See the future of eye care with Aerie.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$993.1M
Total Funding
176
Number of Employees
$24.2M
Revenue (est)
-54%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aerie Pharmaceuticals News
Inotek Pharmaceuticals, Aerie pharmaceuticals Inc, Teva Pharmaceutical Industry, Bausch & Lomb Incorporated, Allergan plc, Novartis AG,...
Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for...
Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for...
DURHAM — Aerie Pharmaceuticals, a developer of therapies for eye diseases, has launched an offering of $250 million of convertible senior ...
Other Companies in Durham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.2M | 177 | 4% | $692.9M |
#2 | $15M | 177 | 11% | N/A |
#3 | $35.4M | 179 | -8% | N/A |
#4 | $36.2M | 180 | 5% | N/A |
#5 | $35M | 181 | -38% | N/A |
Aerie Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2005-10-13 | $21.0M | A | Alta Partners, Texas Pacific Group Ventures | Article |
| 2011-03-08 | $30.0M | B | Clarus Ventures, Sofinnova Ventures | Article |
| 2013-10-28 | $67.0M | Undisclosed | RBC Capital Markets | Article |
| 2014-09-10 | $125.0M | Undisclosed | Deerfield Management Company | Article |
| 2016-09-19 | $125.0M | Undisclosed | Cantor Fitzgerald & Co | Article |
| 2017-05-26 | $50.0M | Undisclosed | Cantor Fitzgerald & Co. | Article |
| 2018-01-25 | $86.2M | Undisclosed | Cantor Fitzgerald & Co | Article |